Evidence map›Paper›PMID 40969306›Full record

ArticleFrontiers in surgery2025

Porphyrin-based nanotechnology: a minimally invasive approach for drug delivery and cholesteatoma treatment.

Dina Ashraf Mahmoud, Lili Ding, Zannatul Ferdous, Zhifen Zhang, Juan Chen, Jennifer L Spiegel, Edward Alexander Sykes, Robert Harrison, Gang Zheng, Trung Le

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Dina Ashraf MahmoudTemerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Lili DingPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Zannatul FerdousBiological Sciences Platform, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, ON, Canada.
Zhifen ZhangBiological Sciences Platform, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, ON, Canada.
Juan ChenPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Jennifer L SpiegelBiological Sciences Platform, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, ON, Canada.
Edward Alexander SykesDepartment of Otolaryngology-Head and Neck Surgery, University of Toronto, Toronto, ON, Canada.
Robert HarrisonDepartment of Otolaryngology-Head and Neck Surgery, University of Toronto, Toronto, ON, Canada.
Gang ZhengPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Trung LeBiological Sciences Platform, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The treatment of inner and middle ear diseases remains a significant challenge, often requiring surgical intervention as the only option. In this study, we investigated porphysomes, self-assembled porphyrin-based nanoparticles, as a minimally invasive drug delivery platform for inner ear applications and as photothermal agents for cholesteatoma ablation. Three porphysome formulations were evaluated: parent porphysomes (PS), porphyrin-stabilized nanoemulsions (nPS), and EDTA-lipid incorporated porphysomes (ePS). Rats received intratympanic injections of each formulation, and fluorescence imaging performed 1 h postinjection demonstrated concentration-dependent inner ear penetration for all formulations. Notably, no signs of ototoxicity were observed based on histological and functional assessments of hearing and balance. Among ePS-treated rats, the 250 and 1,000 μM groups showed significantly higher inner ear fluorescence compared with the 50 μM group. Auditory brainstem response (ABR) and distortion product otoacoustic emission (DPOAE) tests were performed at baseline and 2 and 6 weeks postinjection. No significant threshold shifts were detected in PS and ePS groups compared with controls. In contrast, nPS-treated rats exhibited a significant ABR threshold elevation at 6 weeks (

Indexed as

cholesteatomahearing lossinfectioninner ear drug deliverynanoparticlesphotothermal therapyporphysomesregeneration

Identifiers

PMID40969306
PMCPMC12441058

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.